Sign in to view content

Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results

Dilraj S Grewal, MD, FASRS

Video
Published 2023

Related

Integrin Antagonism for DME
Hugo Quiroz-Mercado, MD
Updates from the Field
2019
Severity of Diabetic Retinopathy as an Independent Risk Factor for Cerebral Vascular Accidents, Myocardial Infarctions, and All-Cause Mortality
Bobeck S Modjtahedi, MD
Annual Meeting Talks
2020
Diabetic Retinopathy Part I Take-Home Panel
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2019

Category: Socioeconomics

See more